{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T07:22:06Z","timestamp":1785223326716,"version":"3.55.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T00:00:00Z","timestamp":1716854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T00:00:00Z","timestamp":1716854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21H03070"],"award-info":[{"award-number":["21H03070"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Kenzo Suzuki Foundation"},{"DOI":"10.13039\/100019356","name":"SGH Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019356","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007428","name":"Naito Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007428","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Cancer Translational Research Foundation of Japanese Urological Association"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s11523-024-01068-7","type":"journal-article","created":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T20:36:11Z","timestamp":1716928571000},"page":"635-644","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["C-Reactive Protein-Albumin Ratio Predicts Objective Response to Enfortumab Vedotin in Metastatic Urothelial Carcinoma"],"prefix":"10.1007","volume":"19","author":[{"given":"Taizo","family":"Uchimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumasa","family":"Komura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Fukuokaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Adachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Hirasawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuhiko","family":"Yoshizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanobu","family":"Saruta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamoru","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Higashio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuya","family":"Tsuchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Tsujino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ko","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuo","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyosuke","family":"Nishio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shutaro","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Iwatani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihiko","family":"Urabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichiro","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Yanagisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Tsuduki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Takahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teruo","family":"Inamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Miki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutoshi","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio","family":"Ohno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoichi","family":"Shiroki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotsugu","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruhito","family":"Azuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,28]]},"reference":[{"issue":"17","key":"1068_CR1","doi-asserted-by":"publisher","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","volume":"18","author":"H von der Maase","year":"2000","unstructured":"von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18(17):3068\u201377.","journal-title":"J Clin Oncol"},{"issue":"11","key":"1068_CR2","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","volume":"376","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015\u201326.","journal-title":"N Engl J Med"},{"issue":"10031","key":"1068_CR3","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","volume":"387","author":"JE Rosenberg","year":"2016","unstructured":"Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031):1909\u201320.","journal-title":"Lancet"},{"issue":"4","key":"1068_CR4","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1817323","volume":"381","author":"Y Loriot","year":"2019","unstructured":"Loriot Y, Necchi A, Park SH, Garcia-Donas J, Huddart R, Burgess E, et al. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med. 2019;381(4):338\u201348.","journal-title":"N Engl J Med"},{"issue":"12","key":"1068_CR5","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","volume":"384","author":"T Powles","year":"2021","unstructured":"Powles T, Rosenberg JE, Sonpavde GP, Loriot Y, Duran I, Lee JL, et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med. 2021;384(12):1125\u201335.","journal-title":"N Engl J Med"},{"issue":"7","key":"1068_CR6","first-page":"400","volume":"18","author":"P Sidaway","year":"2021","unstructured":"Sidaway P. Sacituzumab govitecan is safe and effective. Nat Rev Clin Oncol. 2021;18(7):400.","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"1068_CR7","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/iju.15368","volume":"31","author":"W Fukuokaya","year":"2024","unstructured":"Fukuokaya W, Koike Y, Yata Y, Komura K, Uchimoto T, Tsujino T, et al. Real world evidence of enfortumab vedotin in patients with advanced urothelial cancer: a multicenter observational study. Int J Urol. 2024;31(4):342\u20137.","journal-title":"Int J Urol"},{"issue":"4","key":"1068_CR8","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1007\/s00432-024-05717-2","volume":"150","author":"Y Hirasawa","year":"2024","unstructured":"Hirasawa Y, Adachi T, Hashimoto T, Fukuokaya W, Koike Y, Yata Y, et al. Comparison of the efficacy of enfortumab vedotin between patients with metastatic urothelial carcinoma who were treated with avelumab or pembrolizumab: real-world data from a multi-institutional study in Japan. J Cancer Res Clin Oncol. 2024;150(4):182.","journal-title":"J Cancer Res Clin Oncol"},{"key":"1068_CR9","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-024-01047-y","author":"T Uchimoto","year":"2024","unstructured":"Uchimoto T, Tsuchida S, Komura K, Fukuokaya W, Adachi T, Hirasawa Y, et al. Durable response to enfortumab vedotin compared to re-challenging chemotherapy in metastatic urothelial carcinoma after checkpoint inhibitors. Target Oncol. 2024;19(3):401-10.","journal-title":"Target Oncol"},{"issue":"9","key":"1068_CR10","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.1245\/s10434-019-07530-5","volume":"26","author":"K Komura","year":"2019","unstructured":"Komura K, Hashimoto T, Tsujino T, Muraoka R, Tsutsumi T, Satake N, et al. The CANLPH score, an integrative model of systemic inflammation and nutrition status (SINS), predicts clinical outcomes after surgery in renal cell carcinoma: data from a multicenter cohort in Japan. Ann Surg Oncol. 2019;26(9):2994\u20133004.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"1068_CR11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s12032-019-1332-7","volume":"37","author":"T Uchimoto","year":"2019","unstructured":"Uchimoto T, Komura K, Fujiwara Y, Saito K, Tanda N, Matsunaga T, et al. Prognostic impact of C-reactive protein-albumin ratio for the lethality in castration-resistant prostate cancer. Med Oncol. 2019;37(1):9.","journal-title":"Med Oncol"},{"issue":"9","key":"1068_CR12","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1245\/s10434-017-5948-6","volume":"24","author":"T Tsujino","year":"2017","unstructured":"Tsujino T, Komura K, Matsunaga T, Yoshikawa Y, Takai T, Uchimoto T, et al. Preoperative measurement of the Modified Glasgow Prognostic Score predicts patient survival in non-metastatic renal cell carcinoma prior to nephrectomy. Ann Surg Oncol. 2017;24(9):2787\u201393.","journal-title":"Ann Surg Oncol"},{"issue":"11","key":"1068_CR13","doi-asserted-by":"publisher","first-page":"812.e1","DOI":"10.1016\/j.urolonc.2019.04.002","volume":"37","author":"T Tsujino","year":"2019","unstructured":"Tsujino T, Komura K, Hashimoto T, Muraoka R, Satake N, Matsunaga T, et al. C-reactive protein-albumin ratio as a prognostic factor in renal cell carcinoma: a data from multi-institutional study in Japan. Urol Oncol. 2019;37(11):812.e1-8.","journal-title":"Urol Oncol"},{"key":"1068_CR14","doi-asserted-by":"publisher","first-page":"4789","DOI":"10.2147\/CMAR.S180301","volume":"10","author":"Y Guo","year":"2018","unstructured":"Guo Y, Cai K, Mao S, Zhang J, Wang L, Zhang Z, et al. Preoperative C-reactive protein\/albumin ratio is a significant predictor of survival in bladder cancer patients after radical cystectomy: a retrospective study. Cancer Manag Res. 2018;10:4789\u2013804.","journal-title":"Cancer Manag Res."},{"issue":"2","key":"1068_CR15","first-page":"370","volume":"8","author":"M Kunizaki","year":"2018","unstructured":"Kunizaki M, Tominaga T, Wakata K, Miyazaki T, Matsumoto K, Sumida Y, et al. Clinical significance of the C-reactive protein-to-albumin ratio for the prognosis of patients with esophageal squamous cell carcinoma. Mol Clin Oncol. 2018;8(2):370\u20134.","journal-title":"Mol Clin Oncol."},{"issue":"5","key":"1068_CR16","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1002\/hed.25565","volume":"41","author":"A Kuboki","year":"2019","unstructured":"Kuboki A, Kanaya H, Nakayama T, Konno W, Goto K, Nakajima I, et al. Prognostic value of C-reactive protein\/albumin ratio for patients with hypopharyngeal and laryngeal cancer undergoing invasive surgery involving laryngectomy. Head Neck. 2019;41(5):1342\u201350.","journal-title":"Head Neck"},{"issue":"19","key":"1068_CR17","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000006848","volume":"96","author":"YW Koh","year":"2017","unstructured":"Koh YW, Lee HW. Prognostic impact of C-reactive protein\/albumin ratio on the overall survival of patients with advanced nonsmall cell lung cancers receiving palliative chemotherapy. Medicine (Baltimore). 2017;96(19): e6848.","journal-title":"Medicine (Baltimore)"},{"key":"1068_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.879803","volume":"12","author":"M Wu","year":"2022","unstructured":"Wu M, Zhou Y, Chen Q, Yu Z, Gu H, Lin P, et al. Prognostic role of pretreatment C-reactive protein to albumin ratio in urological cancers: a systematic review and meta-analysis. Front Oncol. 2022;12: 879803.","journal-title":"Front Oncol"},{"issue":"1","key":"1068_CR19","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1186\/s12885-023-11565-z","volume":"23","author":"Q Zhou","year":"2023","unstructured":"Zhou Q, He Q, He W, Wang C, Liu G, Wang K, et al. Clinical value of folate receptor-positive circulating tumor cells in patients with esophageal squamous cell carcinomas: a retrospective study. BMC Cancer. 2023;23(1):1171.","journal-title":"BMC Cancer"},{"key":"1068_CR20","doi-asserted-by":"publisher","first-page":"320","DOI":"10.5694\/j.1326-5377.1964.tb115781.x","volume":"2","author":"B Gandevia","year":"1964","unstructured":"Gandevia B, Tovell A. Declaration of Helsinki. Med J Aust. 1964;2:320\u20131.","journal-title":"Med J Aust"},{"issue":"2","key":"1068_CR21","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer"},{"issue":"3","key":"1068_CR22","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","volume":"18","author":"L Seymour","year":"2017","unstructured":"Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18(3):e143\u201352.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1068_CR23","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3","volume":"3","author":"WJ Youden","year":"1950","unstructured":"Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3(1):32\u20135.","journal-title":"Cancer"},{"issue":"8","key":"1068_CR24","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","volume":"22","author":"C Dumontet","year":"2023","unstructured":"Dumontet C, Reichert JM, Senter PD, Lambert JM, Beck A. Antibody-drug conjugates come of age in oncology. Nat Rev Drug Discov. 2023;22(8):641\u201361.","journal-title":"Nat Rev Drug Discov"},{"issue":"22","key":"1068_CR25","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1200\/JCO.20.03489","volume":"39","author":"ST Tagawa","year":"2021","unstructured":"Tagawa ST, Balar AV, Petrylak DP, Kalebasty AR, Loriot Y, Flechon A, et al. TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors. J Clin Oncol. 2021;39(22):2474\u201385.","journal-title":"J Clin Oncol"},{"key":"1068_CR26","doi-asserted-by":"publisher","first-page":"1165510","DOI":"10.3389\/fimmu.2023.1165510","volume":"14","author":"J Zhu","year":"2023","unstructured":"Zhu J, Wang D, Liu C, Huang R, Gao F, Feng X, et al. Development and validation of a new prognostic immune-inflammatory-nutritional score for predicting outcomes after curative resection for intrahepatic cholangiocarcinoma: a multicenter study. Front Immunol. 2023;14:1165510.","journal-title":"Front Immunol"},{"issue":"27","key":"1068_CR27","doi-asserted-by":"publisher","first-page":"3476","DOI":"10.3748\/wjg.v28.i27.3476","volume":"28","author":"Z Zhao","year":"2022","unstructured":"Zhao Z, Yin XN, Wang J, Chen X, Cai ZL, Zhang B. Prognostic significance of hemoglobin, albumin, lymphocyte, platelet in gastrointestinal stromal tumors: a propensity matched retrospective cohort study. World J Gastroenterol. 2022;28(27):3476\u201387.","journal-title":"World J Gastroenterol"},{"issue":"23","key":"1068_CR28","doi-asserted-by":"publisher","first-page":"7055","DOI":"10.3390\/jcm11237055","volume":"11","author":"M Zakosek","year":"2022","unstructured":"Zakosek M, Bulatovic D, Pavlovic V, Filipovic A, Igic A, Galun D, et al. Prognostic Nutritional Index (PNI) and neutrophil to lymphocyte ratio (NLR) as predictors of short-term survival in patients with advanced malignant biliary obstruction treated with percutaneous transhepatic biliary drainage. J Clin Med. 2022;11(23):7055.","journal-title":"J Clin Med"},{"issue":"1","key":"1068_CR29","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s10147-021-02061-0","volume":"27","author":"T Yanagisawa","year":"2022","unstructured":"Yanagisawa T, Mori K, Katayama S, Mostafaei H, Quhal F, Laukhtina E, et al. Pretreatment clinical and hematologic prognostic factors of metastatic urothelial carcinoma treated with pembrolizumab: a systematic review and meta-analysis. Int J Clin Oncol. 2022;27(1):59\u201371.","journal-title":"Int J Clin Oncol"},{"issue":"5b","key":"1068_CR30","doi-asserted-by":"publisher","first-page":"E137","DOI":"10.1111\/bju.12564","volume":"113","author":"GR Pond","year":"2014","unstructured":"Pond GR, Agarwal N, Bellmunt J, Choueiri TK, Qu A, Fougeray R, et al. A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma. BJU Int. 2014;113(5b):E137\u201343.","journal-title":"BJU Int"},{"issue":"6","key":"1068_CR31","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/j.eururo.2014.02.042","volume":"66","author":"BR Viers","year":"2014","unstructured":"Viers BR, Boorjian SA, Frank I, Tarrell RF, Thapa P, Karnes RJ, et al. Pretreatment neutrophil-to-lymphocyte ratio is associated with advanced pathologic tumor stage and increased cancer-specific mortality among patients with urothelial carcinoma of the bladder undergoing radical cystectomy. Eur Urol. 2014;66(6):1157\u201364.","journal-title":"Eur Urol"},{"issue":"11","key":"1068_CR32","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1200\/JCO.2009.25.4599","volume":"28","author":"J Bellmunt","year":"2010","unstructured":"Bellmunt J, Choueiri TK, Fougeray R, Schutz FA, Salhi Y, Winquist E, et al. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol. 2010;28(11):1850\u20135.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1068_CR33","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.urolonc.2022.02.012","volume":"40","author":"T Uchimoto","year":"2022","unstructured":"Uchimoto T, Nakamura K, Komura K, Fukuokaya W, Yano Y, Nishimura K, et al. Prognostic value of the fluctuation in the neutrophil-lymphocyte ratio at 6 weeks of pembrolizumab treatment is specific to the clinical response in metastatic urothelial carcinoma. Urol Oncol. 2022;40(7):344 (e11\u20137).","journal-title":"Urol Oncol"},{"issue":"14","key":"1068_CR34","doi-asserted-by":"publisher","first-page":"3554","DOI":"10.3390\/cancers13143554","volume":"13","author":"T Uchimoto","year":"2021","unstructured":"Uchimoto T, Komura K, Fukuokaya W, Kimura T, Takahashi K, Yano Y, et al. Risk classification for overall survival by the neutrophil-lymphocyte ratio and the number of metastatic sites in patients treated with pembrolizumab: a multicenter collaborative study in Japan. Cancers (Basel). 2021;13(14):3554.","journal-title":"Cancers (Basel)."},{"issue":"2","key":"1068_CR35","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41585-020-00394-5","volume":"18","author":"EI Heath","year":"2021","unstructured":"Heath EI, Rosenberg JE. The biology and rationale of targeting nectin-4 in urothelial carcinoma. Nat Rev Urol. 2021;18(2):93\u2013103.","journal-title":"Nat Rev Urol"},{"issue":"4","key":"1068_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2023.188902","volume":"1878","author":"S Qiu","year":"2023","unstructured":"Qiu S, Zhang J, Wang Z, Lan H, Hou J, Zhang N, et al. Targeting Trop-2 in cancer: recent research progress and clinical application. Biochim Biophys Acta Rev Cancer. 2023;1878(4): 188902.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"1","key":"1068_CR37","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003868","volume":"10","author":"K Nishimura","year":"2022","unstructured":"Nishimura K, Nishio K, Hirosuna K, Komura K, Hayashi T, Fukuokaya W, et al. Efficacy of pembrolizumab and comprehensive CD274\/PD-L1 profiles in patients previously treated with chemoradiation therapy as radical treatment in bladder cancer. J Immunother Cancer. 2022;10(1): e003868.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"1068_CR38","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s12943-023-01897-6","volume":"22","author":"K Komura","year":"2023","unstructured":"Komura K, Hirosuna K, Tokushige S, Tsujino T, Nishimura K, Ishida M, et al. The impact of FGFR3 alterations on the tumor microenvironment and the efficacy of immune checkpoint inhibitors in bladder cancer. Mol Cancer. 2023;22(1):185.","journal-title":"Mol Cancer"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-024-01068-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-024-01068-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-024-01068-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T17:11:23Z","timestamp":1720458683000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-024-01068-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,28]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["1068"],"URL":"https:\/\/doi.org\/10.1007\/s11523-024-01068-7","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,28]]},"assertion":[{"value":"6 May 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Kazumasa Komura was partially supported by Grant-in-Aid No. 21H03070 (Japan Society for the Promotion of Science), the Kenzo Suzuki Memorial Foundation, the SGH Foundation, the Naito Memorial Foundation, and the Cancer Translational Research Foundation of Japanese Urological Association.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Taizo Uchimoto, Takuya Matsuda, Kazumasa Komura, Wataru Fukuokaya, Takahiro Adachi, Yosuke Hirasawa, Takeshi Hashimoto, Atsuhiko Yoshizawa, Masanobu Saruta, Mamoru Hashimoto, Takuya Higashio, Shuya Tsuchida, Kazuki Nishimura, Takuya Tsujino, Ko Nakamura, Tatsuo Fukushima, Kyosuke Nishio, Shutaro Yamamoto, Kosuke Iwatani, Fumihiko Urabe, Keiichiro Mori, Takafumi Yanagisawa, Shunsuke Tsuduki, Kiyoshi Takahara, Teruo Inamoto, Jun Miki, Kazutoshi Fujita, Takahiro Kimura, Yoshio Ohno, Ryoichi Shiroki, Hirotsugu Uemura, and Haruhito Azuma have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"This study was approved by the Institutional Review Board of Osaka Medical and Pharmaceutical University (approval number: RIN-750-2571, approved on 24 January, 2020). This observational study adhered to ethical principles aligned with the Declaration of Helsinki, the International Conference on Harmonisation\u2019s Good Clinical Practice guidelines, Good Pharmacoepidemiology Practices, and relevant laws for non-interventional and observational studies.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All patients provided written informed consent prior to data collection for the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The data from this study can be accessed by academic and commercial partners upon a reasonable request, subject to institutional review board approval and a data use agreement. For further details or to reanalyze the study\u2019s data, contact the Lead Contact at kazumasa.komura@ompu.ac.jp.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"TU: conceptualization, data curation, analysis, investigation, methodology, software, visualization, writing original draft, supervision. TM: data curation, analysis, investigation, methodology, software, visualization. KK: data curation, investigation, investigation, writing the original draft, supervision. WF: investigation, data curation, validation. AA: validation, methodology. YH: methodology, validation. TH: methodology, validation. AY: data curation. MS: data curation. MH: analysis. TH: data curation, analysis. ST: investigation. KN: data curation. TT: methodology, data curation. KN: investigation. TF: data curation, analysis. KN: validation. SY: data curation. KI: investigation, supervision. FU: investigation, validation, supervision. KM: methodology, data analysis. TY: investigation. ST: writing original draft, review. KT: editing, supervision. TI: data curation. JM: data curation, analysis. KF: review and editing, supervision. TK: investigation, validation, supervision. YO: supervision. RS: supervision. HU: supervision. HA: supervision.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}